Please assess the completion status of the following clinical trial:

Trial Title: Low-dose Nifedipine-Valsartan Combination Compared to Up-titrated Valsartan Monotherapy in Essential Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women aged 18 - 75 years~* Essential hypertension not well controlled by current low dose (80 mg) valsartan monotherapy for at least 4 weeks. Patients on prior treatment with monotherapy diuretic, ACE-I or beta blocker or an ARB other than valsartan and switched to the current low dose valsartan 80 mg monotherapy for at least 4 weeks are also eligible, provided the hypertension is still not well controlled.~* Office systolic blood pressure (sitting) \>140 mmHg (sitting for \>/= 5 min., no cigarettes and/or coffee/tea for \>/=30 min. before BP measurement).~* BMI \<33 kg/m2~Exclusion Criteria:~* Participation in any clinical investigational drug study within the previous 12 weeks~* Concomitant treatments with:~  1. Any anti-hypertensive treatment other than Valsartan 80 mg~ 2. Cytochrome P450-3A4 inhibitors or inducers~ 3. Potassium-sparing diuretics~* Severe hypertension (DBP \>/= 110 mm Hg and/or SBP \>/= 180 mm Hg) and/or evidence of secondary forms of hypertension~* Any of the following cardiovascular diseases:~* History of cardiovascular shock~* Myocardial infarction or unstable angina within the previous 6 months~* Severe cardiac valve disease~* Past or present severe rhythm or conduction disorder.~* Cerebrovascular ischemic event and/or history of intracerebral hemorrhage or subarachnoid hemorrhage (SAH) within the previous 12 months~* Type 1 or 2 diabetes mellitus~* Proteinuria~* Uncorrected hypokalemia or hyperkalemia, sodium depletion and/or hypovolemia~* Gastrointestinal disease resulting in the potential for malabsorption and/or severe gastro-intestinal tract narrowing; kock pouch (ileostomy after proctocolectomy)~* Cholestasis or biliary obstruction~* Liver disease or aspartate aminotransferase (AST) / alanine aminotransferase (ALT) levels \>3 x upper limits of normal (ULN)~* Renal failure, creatinine level \>2.0 mg/dl

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None
- Arm 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).